Synovus Financial Corp Acquires 3,038 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Synovus Financial Corp lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 13.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,639 shares of the medical equipment provider's stock after purchasing an additional 3,038 shares during the quarter. Synovus Financial Corp's holdings in Lantheus were worth $2,294,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. HighTower Advisors LLC bought a new stake in shares of Lantheus during the 3rd quarter worth approximately $607,000. MML Investors Services LLC lifted its stake in Lantheus by 24.6% in the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider's stock valued at $476,000 after acquiring an additional 857 shares during the last quarter. M&T Bank Corp grew its position in shares of Lantheus by 40.4% in the 3rd quarter. M&T Bank Corp now owns 6,847 shares of the medical equipment provider's stock valued at $752,000 after acquiring an additional 1,969 shares during the period. Geode Capital Management LLC increased its stake in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Finally, Coldstream Capital Management Inc. bought a new stake in shares of Lantheus in the 3rd quarter valued at about $230,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on LNTH shares. B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Trading Up 0.8 %

LNTH stock traded up $0.80 during trading hours on Friday, hitting $101.32. 430,521 shares of the stock were exchanged, compared to its average volume of 955,268. Lantheus Holdings, Inc. has a 12 month low of $61.47 and a 12 month high of $126.89. The company has a 50-day simple moving average of $95.00 and a two-hundred day simple moving average of $95.55. The firm has a market capitalization of $6.94 billion, a P/E ratio of 16.86 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.